LSO - Life Sciences Ontario - prepared an in-depth and informative report on the importance of the life science sector in Ontario. TIAP was one of the endorsing organizations. The report was published in May 2021.
MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ...
TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor.
Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein.
The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector:
At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage.
You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ...
TORONTO, ON (May 2, 2014) – MaRS Innovation congratulates the government's deepened commitment to support the life sciences through research and innovation funding. In particular, the new $30 million Life Sciences Seed Venture Capital Fund will create a partnership between the Province of Ontario, the private sector and hospital foundations to finance Ontario-based life sciences companies.
“As co-designers of this venture capital fund and one of its many champions, MaRS Innovation welcomes this news,” says Dr. Raphael (Rafi) Hofstein, president and CEO. ...
Indiegogo campaign raised $53,390 from over 500 worldwide donors
CTV National News featured WaveCheck’s crowdfunding campaign on December 15 in a report by Avis Favaro. The report included an interview with MaRS Innovation’s President and CEO, Dr. Raphael Hofstein (at the 1:37 mark).
William Tran, a researcher associated with the project at Sunnybrook Health Sciences Centre, was also interviewed on Canada AM on December 16.
WaveCheck, which closed its campaign December 4, was invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and ...
The Cellax technology was profiled in a recent issue of SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology's commercialization agent.
Here's an excerpt:
"Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the ...
“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in "Looking for ways to get 'skin' in the game," published in the Financial Post on July 15.
The article focuses on MaRS Innovation's (MI) and the Innovations and Partnerships Office's (University of Toronto) joint efforts to commercialize the bio printer, a "prototype 3D printer that, instead of extruding layers ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein.
The article explores the role of catalysis in building Canada's Life Sciences sector:
In chemistry, according to Encyclopædia Britannica Online, a catalyst is any substance that increases a reaction’s rate without itself being consumed. Kinetically, Wikipedia tells us, catalytic reactions are typical chemical reactions where the reaction rate depends on the reactants’ frequency of contact in the rate-determining step. Usually, ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.
The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ...
May 2, 2013
in DLVR Therapeutics Inc, Encycle Therapeutics, Government Partners, Industry Partners, International Projects, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, ScarX Therapeutics, Start-Up Companies, The Hospital for Sick Children (SickKids), University of Toronto